Joan Shen ends the year by say­ing good­bye to I-Mab; CRISPR Ther­a­peu­tics puts coal in R&D chief's stock­ing

Deck the halls with more ap­point­ments in the last Peer Re­view for 2021. Thanks for read­ing every week!

→ When the cal­en­dar flips to 2022, Joan Shen is out at I-Mab “to pur­sue oth­er in­ter­ests,” leav­ing founder and chair­man Jing­wu Zang to suc­ceed her as act­ing CEO in a bit of a sur­prise. Un­der Shen’s lead­er­ship, I-Mab formed a CD47 al­liance with Ab­b­Vie in Sep­tem­ber 2020 with lem­zopar­limab as the cen­ter­piece, and a year lat­er our Am­ber Tong de­tailed I-Mab’s as­pi­ra­tions for oth­er com­pa­ra­ble part­ner­ships, no­tably for de­vel­op­ment of the CD73 an­ti­body uliledlimab. Shen was one of our 20 Women in Bio­phar­ma R&D hon­orees this month.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER